Internal Application No PCT/IB2004/003882

A. CLASSII IPC 7	REATION OF SUBJECT MATTER A61K47/48 A61K39/00	A61K38/00 A	61K7/40	A61P17/00
A constinu	International Patent Classification (IPC) or to both	national classification and IPC	•	
	SEARCHED	Handrian existence in the in the		
	cumentation searched (classification system follow A61K A61P	red by classification symbols)		
Oocumental	ion searched other than minimum documentation to	the extent that such docume	nts are included in	the fields searched
Electronic d	ata base consulted during the international search	(name of data base and, whe	re practical, search	terms used)
EPO-In	ternal, BIOSIS, WPI Data, F	AJ		
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with Indication, where appr	opriate, of the relevant passa	ges	Relevant to claim No.
X	FOUSSAT ARNAUD ET AL: "study between T regulate CD4+CD25+ T cells in the inflammation." JOURNAL OF IMMUNOLOGY (E1950) 15 NOV 2003, vol. 171, no. 10, 7 November 2003 (2003-115018-5026, XP002292996 According to the data printernet website <a href="http://www.jimmunol.org">http://www.jimmunol.org</a> tml> this article was avoublic on November 7th 2 the whole document	e control of SALTIMORE, MD. : -07), pages covided on the y/misc/postdates to the	/sh	1-44
X Furt	ner documents are listed in the continuation of box	С. Х Ра	tent family member	s are listed in annex.
*A" document defining the general state of the art which is not considered to be of particular relevance  *E" earlier document but published on or after the international filing date  *L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  *O" document referring to an oral disclosure, use, exhibition or other means  *P" document published prior to the international filing date but later than the priority date claimed  *Date of the actual completion of the international search  *T" later document published after the international filing date or priority date and not in conflict with the application but cled to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  *A" document published after the international filing date or priority date and not in conflict with the application but cled to understand the principle or theory underlying the consolider to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the cled to understand the principle or theory underlying the				
	July 2005		2/08/2005	
Name and (	mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  Fax: (+31-70) 340-3016	2	ized officer	

Internal Application No
PCT/IB2004/003882

Category *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
negory *	Citation of document, with Indication, where appropriate, of the relevant passages	neievani to ciaim No.
4	US 2002/034500 A1 (LEVINGS MEGAN K ET AL) 21 March 2002 (2002-03-21) the whole document	1-44
A	AKDIS C A ET AL: "INHIBITION OF T HELPER 2-TYPE RESPONSES, IGE PRODUCTION AND EOSINOPHILIA BY SYNTHETIC LIPOPEPTIDES" EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 33, no. 10, October 2003 (2003-10), pages 2717-2726, XP009034494	1-44
	ISSN: 0014-2980 the whole document	
Α	WO 02/092793 A (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM; GROU) 21 November 2002 (2002-11-21) the whole document	1-44
Α	WO 97/42324 A (SCHERING CORPORATION) 13 November 1997 (1997-11-13) the whole document	1-44
Α	ROUAIX F ET AL: "Effect of a lipopeptidic formulation on macrophage activation and peptide presentation to T cells" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 12, no. 13, 1994, pages 1209-1214, XP002082968 ISSN: 0264-410X the whole document	1-44
Α	GROUX H: "TYPE 1 T-REGULATORY CELLS: THEIR ROLE IN THE CONTROL OF IMMUNE RESPONSES" TRANSPLANTATION, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 75, no. 9, SUPPL, 15 May 2003 (2003-05-15), pages 8S-12S, XP008025406 ISSN: 0041-1337 the whole document	1-44
A	PICHLER W J ET AL: "CELLULAR AND MOLECULAR PATHOPHYSIOLOGY OF CUTANEOUS DRUG REACTIONS"  AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, ADIS,, US, vol. 3, no. 4, 2002, pages 229-238, XP009034499  ISSN: 1175-0561 the whole document	1-44

nal Application No PCT/IB2004/003882

C (Continu	ntion) DOCIMENTS CONSUMERS TO SECOND	PCT/IB2004/003882		
Category *	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	US 5 498 420 A (MENTRUP EDGAR ET AL) 12 March 1996 (1996-03-12) the whole document	1-44		
	<del></del>			
		·		
,				
	•			
.				
	0 (continuation of second sheet) (January 2004)			



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-28 and 36-41 are directed to a method of treatment of the human/animal body by therapy (Rule 39.1(iv) PCT), the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.:  because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of Invention is lacking (Continuation of Item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2004)

ormation on patent issuing members

Internal Application No PCT/IB2004/003882

Patent document cited in search report		Publication date		Patent family member(s)	· — — —	Publication date
US 2002034500	A1	21-03-2002	NONE			
WO 02092793	A	21-11-2002	FR	2824567	A1	15-11-2002
			CA	2446981	A1	21-11-2003
			EP	1390474	A1	25-02-2004
			WO	02092793	A1	21-11-2002
			JP	2004526459	-	02-09-2004
			US	2004191235	A1	30-09-2004
WO 9742324	Α	13-11-1997	US	6277635	B1	21-08-2001
			AU		Α	26-11-1997
			BR	9709307	Α	10-08-1999
			CA	2253803		13-11-1997
			CZ	9803477		17-03-1999
			EP	0906428	A1	07-04-1999
			JP	2000509604	T	02-08-2000
			KR	2000010799	Α	25-02-2000
			NO		Α	06-01-1999
			NZ		Α	27-10-2000
			PL	329732		12-04-1999
			SK	151898		10-04-2000
			WO	9742324	–	13-11-1997
			US	6884410		26-04-2005
			ZA 	9703815	A 	03-11-1997
US 5498420	Α	12-03-1996	DE	4111982		15-10-1992
			AT		T	15-09-1995
			CA	2065579		13-10-1992
			DE	59203259		21-09-1995
			DK	509338		18-09-1995
		•	EP	0509338		21-10-1992
			ES	2077904		01-12-1995
			GR	3017147		30-11-1995
			JP	7048247	А	21-02-1995